Related references
Note: Only part of the references are listed.LONG-TERM VISUAL OUTCOMES AND CLINICAL FEATURES AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTION-RELATED ENDOPHTHALMITIS
Nadim Rayess et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2019)
Changes in Management Based on Vitreous Culture in Endophthalmitis After Intravitreal Anti-vascular Endothelial Growth Factor Injection
Samir N. Patel et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2019)
Treat and extend regimen with aflibercept for chronic central retinal vein occlusions: 2 year results of the NEWTON study
Rahul N. Khurana et al.
INTERNATIONAL JOURNAL OF RETINA AND VITREOUS (2019)
Mechanism of fibrosis inhibition in laser induced choroidal neovascularization by doxycycline
Xuening Peng et al.
EXPERIMENTAL EYE RESEARCH (2018)
Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial
Charles C. Wykoff et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2018)
Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema TREX-DME 1 Year Outcomes
John F. Payne et al.
OPHTHALMOLOGY (2017)
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Maria Waizel et al.
BMC OPHTHALMOLOGY (2017)
Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results
Pedro Neves Cardoso et al.
JOURNAL OF OPHTHALMOLOGY (2017)
Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-related Macular Degeneration: A Prospective Clinical Trial
Francis Char Decroos et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2017)
Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid
Glenn J. Jaffe et al.
OPHTHALMOLOGY (2016)
MICROBIAL SPECTRUM AND OUTCOMES OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION VERSUS PARS PLANA VITRECTOMY
Sunir J. Garg et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2016)
Endophthalmitis following intravitreal injection of anti-VEGF agents: long-term outcomes and the identification of unusual micro-organisms
Mira M. Sachdeva et al.
JOURNAL OF OPHTHALMIC INFLAMMATION AND INFECTION (2016)
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
John A. Wells et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration TREX-AMD 1-Year Results
Charles C. Wykoff et al.
OPHTHALMOLOGY (2015)
The Role of Topical Antibiotic Prophylaxis to Prevent Endophthalmitis after Intravitreal Injection
Philip Storey et al.
OPHTHALMOLOGY (2014)
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration Ninety-Six-Week Results of the VIEW Studies
Ursula Schmidt-Erfurth et al.
OPHTHALMOLOGY (2014)
Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials RISE and RIDE
David M. Brown et al.
OPHTHALMOLOGY (2013)
Sustained Benefits from Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: 12-Month Outcomes of a Phase III Study
David M. Brown et al.
OPHTHALMOLOGY (2011)
Outcomes and Risk Factors Associated with Endophthalmitis after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents
Chirag P. Shah et al.
OPHTHALMOLOGY (2011)
ENDOPHTHALMITIS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ANTAGONISTS A Six-Year Experience at a University Referral Center
Andrew A. Moshfeghi et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2011)
Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
David M. Brown et al.
OPHTHALMOLOGY (2009)
Share Paper
